1/1
2 files

Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis

figure
posted on 16.11.2020, 09:33 authored by Edward E. Neuberger, Ibrahim M. Abbass, Eddie Jones, Natalie J. Engmann

Article full text


The above summary slide and plain language summary represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2020.

History